U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: description was created based on several sources, including http://reference.medscape.com/drug/neo-fradin-myciguent-neomycin-po-342515

Neomycin is an aminoglycoside antibiotic found in many topical medications such as creams, ointments, and eye drops. In vitro tests have demonstrated that neomycin is bactericidal and acts by inhibiting the synthesis of protein in susceptible bacterial cells. It is effective primarily against gram-negative bacilli but does have some activity against gram-positive organisms. Neomycin is active in vitro against Escherichia coli and the Klebsiella-Entero. Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other anti-infective), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in bacteriuria patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enter pathogenic E. coli (EPEC). Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, susceptible bacteria should use Neomycin Sulfate Oral Solution only to treat or prevent infections that are proven or strongly suspected to be caused. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site near nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CVP TRIPLE ANTIBIOTIC

Approved Use

Uses: first aid to help prevent infection in minor: cuts, scrapes, burns

Launch Date

8.1898563E11
Palliative
NEO-FRADIN

Approved Use

Hepatic coma (portal-systemic encephalopathy): Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, Neomycin Sulfate Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

9.9048961E11
PubMed

PubMed

TitleDatePubMed
The evaluation of neomycin and other antimicrobial agents of bacterial and fungal origin, and substances from higher plants.
1949 Dec 14
[Acute kidney failure in patients with pancreatitis treated with neomycin].
1975 Jun 1
A simple classification method for residual antibiotics using E. coli cells transformed by the calcium chloride method and drug resistance plasmid DNA.
2001
Wound healing activity of human placental extracts in rats.
2001 Dec
An integrated method for the enrichment and selective isolation of Actinokineospora spp. in soil and plant litter.
2001 Jul
Aminoglycoside binding displaces a divalent metal ion in a tRNA-neomycin B complex.
2001 Jun
Acute hemorrhagic keratoconjunctivitis after LASIK.
2001 Mar
Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations.
2001 May
Outcome of 22 cases of perforated tympanic membrane caused by otomycosis.
2001 Nov
Stereospecificity of aminoglycoside-ribosomal interactions.
2002 Aug 20
Absorption studies on aminoglycoside binding to the packaging region of human immunodeficiency virus type-1.
2002 Feb 25
Anti-HIV activity of a novel aminoglycoside-arginine conjugate.
2002 Jan
Inhibition of bacterial RNase P by aminoglycoside-arginine conjugates.
2002 Jan 30
Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening.
2002 Jun
Tularemia of the middle ear.
2002 Mar
Inhibition of protein synthesis by aminoglycoside-arginine conjugates.
2002 Oct
Comparison of compliance between topical aural medications.
2003 Aug
Effectiveness of ototopical antibiotics for chronic suppurative otitis media in Aboriginal children: a community-based, multicentre, double-blind randomised controlled trial.
2003 Aug 18
Effect of neomycin B on rotavirus plus- and minus-strand RNA synthesis.
2003 Jun
The Tat antagonist neomycin B hexa-arginine conjugate inhibits gp-120-induced death of human neuroblastoma cells.
2003 Mar
Aminoglycoside antibiotics reduce glucose reabsorption in kidney through down-regulation of SGLT1.
2003 Sep 5
Integrated, long term, sustainable, cost effective biosolids management at a large Canadian wastewater treatment facility.
2004
Inhibition of the proteolytic activity of anthrax lethal factor by aminoglycosides.
2004 Apr 21
Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa.
2004 Aug
The use of perioperative Sofradex eardrops in preventing tympanostomy tube blockage: a prospective double-blinded randomized-controlled trial.
2004 Dec
Changing patterns of contact allergy in chronic inflammatory ear disease.
2004 Feb
An approach to enhance specificity against RNA targets using heteroconjugates of aminoglycosides and chloramphenicol (or linezolid).
2004 Feb 25
Ototoxicity after use of neomycin eardrops is unrelated to A1555G point mutation in mitochondrial DNA.
2004 Jul
Optimizing the quadruple-potential waveform for the pulsed amperometric detection of neomycin.
2004 Jun 11
Interactions of the antibiotics neomycin B and chlortetracycline with the hammerhead ribozyme as studied by Zn2+-dependent RNA cleavage.
2004 Mar 1
Randomized, double-blind trial comparing topical nitroglycerine with xylocaine and Proctosedyl in idiopathic chronic anal fissure.
2004 May-Jun
Molecular evaluation of residual endodontic microorganisms after instrumentation, irrigation and medication with either calcium hydroxide or Septomixine.
2004 Nov
Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme.
2004 Nov 3
The efficacies of affected-limb care with penicillin diethylcarbamazine, the combination of both drugs or antibiotic ointment, in the prevention of acute adenolymphangitis during bancroftian filariasis.
2004 Oct
Delayed neurotrophic treatment preserves nerve survival and electrophysiological responsiveness in neomycin-deafened guinea pigs.
2004 Oct 1
Chemoenzymatic synthesis and high-throughput screening of an aminoglycoside-polyamine library: identification of high-affinity displacers and DNA-binding ligands.
2004 Oct 6
A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication.
2004 Sep 23
Disaccharide mimetics of the aminoglycoside antibiotic neamine.
2004 Sep 6
[The effectiveness of some methods in eliminating bacteria from the root canal of a tooth with chronic apical periodontitis].
2005
A blinded in-vitro study to compare the efficacy of five topical ear drops in clearing grommets blocked with thick middle ear effusion fluid.
2005 Feb
Binding of manganese(II) to a tertiary stabilized hammerhead ribozyme as studied by electron paramagnetic resonance spectroscopy.
2005 Jan
The RNA-bound conformation of neamine as determined by transferred NOE experiments.
2005 Jul
Neamine derivatives having a nucleobase with a lysine or an arginine as a linker, their synthesis and evaluation as potential inhibitors for HIV TAR-Tat.
2006 Apr 15
Trisaccharide mimetics of the aminoglycoside antibiotic neomycin.
2006 Apr 7
Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance.
2006 Jan 11
Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides.
2006 Jul
Neonatal deafness results in degraded topographic specificity of auditory nerve projections to the cochlear nucleus in cats.
2006 Jul 1
Biosolids from two-stage bioleaching could produce compost for unrestricted use.
2006 Jun
The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle.
2006 Mar 21
Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in community-acquired primary pyoderma.
2006 Mar-Apr
Patents

Sample Use Guides

Hepatic coma: 4-12 grams per day given in the following regimen: 1. Withdraw protein from diet. Avoid use of diuretic agents. 2. Give supportive therapy including blood products, as indicated. 3. Give NEO-FRADIN Oral Solution in doses of four to twelve grams of neomycin sulfate per day in divided doses. Treatment should be continued over a period of five to six days during which time protein should be returned incrementally to the diet.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: TRMU, tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase, is expressed in both hair cells and HEI-OC-1 cells, and its expression is significantly decreased after 24 h neomycin treatment. Downregulated TRMU expression with siRNA and found that cell death and apoptosis were significantly increased after neomycin injury.
Unknown
Name Type Language
NEOMYCIN
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NEOMIN
Brand Name English
NEOMYCIN [HSDB]
Common Name English
PIMAVECORT
Brand Name English
NEOMYCIN [VANDF]
Common Name English
ANTIBIOTIC COMPLEX COMPOSED OF NEOMYCINS A, B AND C PRODUCED BY STREPTOMYCES FRADIAE
Common Name English
NEOMYCIN [WHO-DD]
Common Name English
NEOMYCIN [MI]
Common Name English
NEOMAS
Brand Name English
NEOMYCIN [INN]
Common Name English
NEOLATE
Brand Name English
KAOMYCINE
Brand Name English
VONAMYCIN
Brand Name English
FRADIOMYCIN
Common Name English
Classification Tree Code System Code
CFR 21 CFR 524.154
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QD06AX04
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
NDF-RT N0000007853
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QS03AA01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 520.1921
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QB05CA09
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484E
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
NCI_THESAURUS C2363
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 333.120
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484K
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QG51AG03
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC D06AX04
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
EPA PESTICIDE CODE 6303
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC A07AA01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QA01AB08
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC A07AA51
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QG51AG06
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QJ51RG01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QA07AA51
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC S01AA03
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
LIVERTOX 676
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC A01AB08
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484J
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.155
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484H
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC S02AA07
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.960
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QJ01GB05
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 520.1484
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QS02AA07
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484D
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC R02AB01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QS01AA03
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC J01GB05
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QS02AA57
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484F
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484I
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC S03AA01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QA07AA01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484B
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 556.430
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1600A
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 558.455
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
NDF-RT N0000175477
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 520.82B
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-ATC B05CA09
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484C
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.981C
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1484G
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
CFR 21 CFR 524.1600B
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
WHO-VATC QR02AB01
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
Code System Code Type Description
MESH
D009355
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
DRUG CENTRAL
4247
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
WIKIPEDIA
NEOMYCIN
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
LACTMED
Neomycin
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
EVMPD
SUB03406MIG
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
ECHA (EC/EINECS)
215-766-3
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
NCI_THESAURUS
C683
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
MERCK INDEX
M7809
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY Merck Index
EPA CompTox
1404-04-2
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
INN
232
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
HSDB
3242
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL184618
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
RXCUI
7299
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY RxNorm
IUPHAR
709
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
CAS
1404-04-2
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
DRUG BANK
DB00994
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
FDA UNII
I16QD7X297
Created by admin on Sat Jun 26 18:18:22 UTC 2021 , Edited by admin on Sat Jun 26 18:18:22 UTC 2021
PRIMARY
All of the following components must be present:
Definition References